(Q73345501)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

main subject

phase II clinical trial

1 reference

1 reference

S Fields-Jones

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

A Koletsky

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

G Wilding

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M O'Rourke

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

T O'Rourke

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

J Eckardt

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

B Yates

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

C McGuirt

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

H A Burris

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 November 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

1307-1310

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008315106697

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008315106697

7 January 2021

Methods for measuring clinical pain in humans

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008315106697

7 January 2021

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008315106697

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008315106697

7 January 2021

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008315106697

7 January 2021

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008315106697

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008315106697

7 January 2021

Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008315106697

7 January 2021

Identifiers

DOI

10.1023/A:1008315106697

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10631457%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference